IL210866A - Antibodies directed against 1-mcp pyroglutamate (1-mcp pe1n) - Google Patents
Antibodies directed against 1-mcp pyroglutamate (1-mcp pe1n)Info
- Publication number
- IL210866A IL210866A IL210866A IL21086611A IL210866A IL 210866 A IL210866 A IL 210866A IL 210866 A IL210866 A IL 210866A IL 21086611 A IL21086611 A IL 21086611A IL 210866 A IL210866 A IL 210866A
- Authority
- IL
- Israel
- Prior art keywords
- n1pe
- pyroglutamate
- mcp
- directed against
- antibodies directed
- Prior art date
Links
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 title 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 title 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 title 1
- 102000000018 Chemokine CCL2 Human genes 0.000 title 1
- 229940043131 pyroglutamate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9026408P | 2008-08-20 | 2008-08-20 | |
| PCT/EP2009/060757 WO2010020669A1 (en) | 2008-08-20 | 2009-08-20 | Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL210866A0 IL210866A0 (en) | 2011-04-28 |
| IL210866A true IL210866A (en) | 2015-11-30 |
Family
ID=41259004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL210866A IL210866A (en) | 2008-08-20 | 2011-01-25 | Antibodies directed against 1-mcp pyroglutamate (1-mcp pe1n) |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8518406B2 (enExample) |
| EP (1) | EP2328930B1 (enExample) |
| JP (1) | JP5819194B2 (enExample) |
| AU (1) | AU2009284092B2 (enExample) |
| CA (1) | CA2734800C (enExample) |
| DK (1) | DK2328930T3 (enExample) |
| ES (1) | ES2533493T3 (enExample) |
| IL (1) | IL210866A (enExample) |
| NZ (1) | NZ591187A (enExample) |
| PL (1) | PL2328930T3 (enExample) |
| WO (1) | WO2010020669A1 (enExample) |
| ZA (1) | ZA201100658B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| US8829041B2 (en) | 2006-06-23 | 2014-09-09 | Abbvie Inc. | Cyclopropyl amine derivatives |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| SG182615A1 (en) * | 2010-02-18 | 2012-08-30 | Probiodrug Ag | Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| RU2476880C1 (ru) * | 2011-08-25 | 2013-02-27 | Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации | Способ диагностики гестоза тяжелой степени |
| WO2015085171A1 (en) * | 2013-12-06 | 2015-06-11 | Adventist Health Systems/Sunbelt, Inc. | Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2023213400A1 (en) * | 2022-05-05 | 2023-11-09 | Institute For Research In Biomedicine | Antibodies against chemokines, method for identifying said antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4504733A (en) * | 1984-05-15 | 1985-03-12 | Sybron Corporation | Dry bath temperature control |
| US5229580A (en) * | 1992-06-09 | 1993-07-20 | Automated Biosystems, Inc. | Block for holding multiple sample tubes for automatic temperature control |
| US6191398B1 (en) * | 1999-09-10 | 2001-02-20 | Barnstead/Thermolyne Corporation | Dry bath temperature control and method |
| AU2001258836A1 (en) | 2000-05-26 | 2001-12-03 | Kensuke Egashira | Preventives and remedies for pulmonary hypertension |
| GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
| ES2365606T3 (es) * | 2002-02-13 | 2011-10-07 | Ludwig Institute For Cancer Research Ltd. | Anticuerpos contra gm-csf quiméricos. |
| CN1646161A (zh) * | 2002-02-21 | 2005-07-27 | 杜克大学 | 自身免疫疾病的药剂和治疗方法 |
| EP1542724A4 (en) * | 2002-08-19 | 2005-10-19 | Abgenix Inc | ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF |
| KR20050042801A (ko) | 2002-09-12 | 2005-05-10 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 인간형 항인간 ｍｃｐ-1 항체 및 그의 항체 단편 |
| WO2006125201A2 (en) | 2005-05-19 | 2006-11-23 | Centocor, Inc. | Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses |
| PA8675801A1 (es) * | 2005-05-19 | 2006-12-07 | Centocor Inc | Anticuerpos anti-mcp-1, composiciones, metodos y usos |
| BRPI0709050B1 (pt) * | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| US20080056957A1 (en) * | 2006-09-01 | 2008-03-06 | Chemglass, Inc. | Segmented reaction blocks for supporting vials of different sizes for chemical synthesis on a hot plate stirrer |
-
2009
- 2009-08-20 ES ES09782017.9T patent/ES2533493T3/es active Active
- 2009-08-20 US US12/544,319 patent/US8518406B2/en not_active Expired - Fee Related
- 2009-08-20 CA CA2734800A patent/CA2734800C/en not_active Expired - Fee Related
- 2009-08-20 EP EP09782017.9A patent/EP2328930B1/en not_active Not-in-force
- 2009-08-20 NZ NZ591187A patent/NZ591187A/en not_active IP Right Cessation
- 2009-08-20 WO PCT/EP2009/060757 patent/WO2010020669A1/en not_active Ceased
- 2009-08-20 AU AU2009284092A patent/AU2009284092B2/en not_active Ceased
- 2009-08-20 DK DK09782017T patent/DK2328930T3/da active
- 2009-08-20 JP JP2011523422A patent/JP5819194B2/ja not_active Expired - Fee Related
- 2009-08-20 PL PL09782017T patent/PL2328930T3/pl unknown
-
2011
- 2011-01-25 IL IL210866A patent/IL210866A/en active IP Right Grant
- 2011-01-26 ZA ZA2011/00658A patent/ZA201100658B/en unknown
-
2013
- 2013-07-23 US US13/948,363 patent/US9157918B2/en not_active Expired - Fee Related
-
2015
- 2015-08-31 US US14/840,978 patent/US20150361167A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2328930A1 (en) | 2011-06-08 |
| JP2012500016A (ja) | 2012-01-05 |
| AU2009284092B2 (en) | 2016-05-19 |
| US20100119478A1 (en) | 2010-05-13 |
| ES2533493T3 (es) | 2015-04-10 |
| DK2328930T3 (da) | 2015-03-30 |
| PL2328930T3 (pl) | 2015-05-29 |
| ZA201100658B (en) | 2012-05-01 |
| US20150361167A1 (en) | 2015-12-17 |
| WO2010020669A1 (en) | 2010-02-25 |
| JP5819194B2 (ja) | 2015-11-18 |
| CA2734800A1 (en) | 2010-02-25 |
| US20130302835A1 (en) | 2013-11-14 |
| EP2328930B1 (en) | 2014-12-24 |
| US8518406B2 (en) | 2013-08-27 |
| IL210866A0 (en) | 2011-04-28 |
| US9157918B2 (en) | 2015-10-13 |
| CA2734800C (en) | 2021-02-09 |
| AU2009284092A1 (en) | 2010-02-25 |
| NZ591187A (en) | 2012-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL210866A0 (en) | Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) | |
| SI2285409T1 (sl) | Protitelesa il-1 alfa | |
| GB2476608B (en) | Electromagnetic clamping device | |
| EP2241578A4 (en) | ANTI-CLDN6 ANTIBODIES | |
| EP2242433A4 (en) | ANSE DEVICE | |
| EP2243994A4 (en) | MOBILE TENSESITY STRUCTURE | |
| ZA201102119B (en) | Improved antibody libraies | |
| GB0905845D0 (en) | Assembly device | |
| GB0821100D0 (en) | Antibodies | |
| EP3306294C0 (en) | ANALYSIS SYSTEM | |
| EP2281722A4 (en) | PARKING AID DEVICE | |
| IL207581A0 (en) | Anti-tyrp1 antibodies | |
| HUE036824T2 (hu) | Mûködtetõszerkezet | |
| EP2243568A4 (en) | BENDER | |
| GB2460654B (en) | Autofocus system test chart | |
| GB0901538D0 (en) | Electromagnetic imaging analyser | |
| EP2289273A4 (en) | PREDICTION OF BIT RATE | |
| GB2462106B (en) | Assembly device | |
| EP2340195A4 (en) | STAND | |
| GB2456665B (en) | An acoustic device | |
| GB0815239D0 (en) | Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) | |
| GB0911770D0 (en) | Antibody | |
| EP2264071A4 (en) | ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION | |
| GB2445170B (en) | Wire output structure | |
| TWM347424U (en) | Improved bumper structure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |